Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet

Fidaxomicin is a new narrow spectrum macrocyclic antibiotic. It inhibits bacterial RNA polymerase and eradicates C difficile with minimal effect on normal intestinal flora. The US FDA granted orphan drug designation for all formulations of fidaxomicin for the treatment of C difficile infections in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Tanya, So, Tsz-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139813/
https://www.ncbi.nlm.nih.gov/pubmed/27942322
http://dx.doi.org/10.4021/gr318e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139813/
https://www.ncbi.nlm.nih.gov/pubmed/27942322
http://dx.doi.org/10.4021/gr318e

Ejemplares similares